TransMedics Group Inc
$ 83.89
4.59%
07 Aug - close price
- Market Cap 2,908,898,000 USD
- Current Price $ 83.89
- High / Low $ 83.98 / 79.51
- Stock P/E 21.73
- Book Value 14.30
- EPS 3.86
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.36 %
- 52 Week High 156.00
- 52 Week Low 60.10
About
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Analyst Target Price
$98.80
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-02-24 | 2025-10-29 | 2025-07-30 | 2025-05-08 | 2025-02-27 | 2024-10-28 | 2024-07-31 | 2024-04-30 | 2024-02-26 | 2023-11-06 |
| Reported EPS | 0.44 | 0.3 | 0.051 | 0.66 | 0.92 | 0.7 | 0.19 | 0.12 | 0.35 | 0.35 | 0.12 | 0.07 |
| Estimated EPS | 0.5 | 0.61 | 0.3904 | 0.36 | 0.43 | 0.24 | 0.22 | 0.32 | 0.2 | 0.01 | -0.03 | -0.13 |
| Surprise | -0.06 | -0.31 | -0.3394 | 0.3 | 0.49 | 0.46 | -0.03 | -0.2 | 0.15 | 0.34 | 0.15 | 0.2 |
| Surprise Percentage | -12% | -50.8197% | -86.9365% | 83.3333% | 113.9535% | 191.6667% | -13.6364% | -62.5% | 75% | 3400% | 500% | 153.8462% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TMDX
2026-08-09 04:11:33
Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages current shareholders to visit its website or contact them for more information regarding the investigation. Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, with a track record of significant recoveries for investors.
2026-08-07 00:40:37
TransMedics Group Inc (TMDX) shares rose 4.9% to $80.21, but are still estimated to be 48.7% undervalued based on its GF Value™ of $156.29. The stock holds a GF Score™ of 70/100, indicating above-average performance, particularly in growth. However, significant insider selling of $0.7 million and a low valuation rank suggest a potential value trap, prompting caution for investors.
2026-08-06 05:12:03
TransMedics Group Inc (TMDX) reported strong Q2 2026 revenue of ~$190 million, up 21% year-over-year, driven by significant growth in service revenue and logistics market share gains. The company raised its full-year revenue guidance while acknowledging a decline in adjusted operating margin due to increased strategic investments in R&D and clinical programs. Key initiatives include the OCS Kidney program, NextGen platform development, and European expansion through the PAD Aviation acquisition.
2026-08-06 01:09:29
Analysts have cut the 12-month average price target for TransMedics Group, Inc. (TMDX) stock from $106 to $97.3, which still suggests a 20% upside based on its closing price on August 4th. The consensus rating from 12 analysts remains a "Buy," with 8 recommending Buy and 4 recommending Hold.
2026-08-06 00:42:00
TransMedics (TMDX) reported a Q2 2026 earnings per share miss of 44 cents, a 52.2% year-over-year decrease, despite revenues rising 20.7% to $189.9 million. The company's shares dropped 7.8% in after-market trading and are down 33.6% year-to-date. Margins contracted due to increased operating expenses, particularly in research and development, although TransMedics raised the lower end of its full-year 2026 revenue guidance.
2026-08-05 23:35:00
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages TransMedics shareholders to visit its website for more information or contact them directly. Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, with a history of successful settlements for investors.
